NeoGenomics, Inc. (NASDAQ: NEO) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $2.2B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), NeoGenomics, Inc. had a Maz Rating of 4.49 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.54), among the strongest in its sector; its weakest was Valuation (2.07), more expensive than most of its sector. The other factors: Profitability 4.16 (above most of its sector); Growth 3.51 (above most of its sector); Financial Health 3.02 (around the middle of its sector). The current rating is for members: log in to see it.
At $16.83, NeoGenomics, Inc. trades at 2.8x sales and 2.7x book value, with an EV/EBITDA of 77.5. Over the last twelve months it generated about $788M of revenue and a net loss of $32M. It runs a gross margin of 43.8%, an operating margin of -6.0% and a net margin of -4.1%. It shows return on equity of -4.0%, return on invested capital of -3.3% and a free cash flow yield of -1.3%. On the balance sheet: a debt-to-equity ratio of 0.56 and a current ratio of 3.53. Over the past 52 weeks the share price ranged from $7.07 to $20.15, with a beta of 1.83.
NeoGenomics, Inc. does not currently pay a dividend.
30 Wall Street analyst ratings cover the stock: 1 Strong Buy, 23 Buy, 5 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.